Antibe Therapeutics (ATE) News Today Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsEarningsInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period How a mom of two who ‘ate her emotions’ lost over 120 pounds in under a yearAugust 3, 2024 | nypost.comCanadian Investment Regulatory Organization Trading Halt - ATEApril 9, 2024 | finance.yahoo.comAntibe Announces Unfavorable Decision in Arbitration With Nuance PharmaMarch 4, 2024 | finance.yahoo.comAntibe Therapeutics (TSE:ATE) Share Price Passes Above 50-Day Moving Average of $0.92Antibe Therapeutics (TSE:ATE) Stock Price Crosses Above 50-Day Moving Average of $0.92February 9, 2024 | marketbeat.comAntibe Extends Early Warrant Exercise Incentive ProgramFebruary 1, 2024 | finance.yahoo.comAntibe Therapeutics Inc ATEDecember 31, 2023 | morningstar.comAntibe Announces Early Warrant Exercise Incentive ProgramDecember 29, 2023 | finance.yahoo.comAntibe Reports Q2 2024 Interim Financial and Operating ResultsNovember 13, 2023 | finance.yahoo.comAntibe Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)November 8, 2023 | theglobeandmail.comHercules at 52-Week High on Barrick HookupNovember 6, 2023 | baystreet.caAntibe at 52-Week High on NewsNovember 1, 2023 | baystreet.caAntibe Completes First Clinical Study of Otenaproxesul’s New FormulationNovember 1, 2023 | finance.yahoo.comAntibe Initiates First Clinical Study of Otenaproxesul's New FormulationOctober 18, 2023 | benzinga.comStocks in play: Antibe Therapeutics Inc.September 28, 2023 | ca.finance.yahoo.comAntibe Receives Approval to Initiate PK/PD Study of OtenaproxesulSeptember 28, 2023 | finance.yahoo.comAntibe Therapeutics Inc. (ATE)September 6, 2023 | investing.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 21, 2023 | finance.yahoo.comToronto Stock Exchange, Antibe Therapeutics Inc., View From The C-SuiteAugust 21, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc down on Wednesday (ATE)August 17, 2023 | theglobeandmail.comAntibe Therapeutics Inc.'s (TSE:ATE) Path To ProfitabilityJune 30, 2023 | finance.yahoo.comLast Week of June Looks EventfulJune 23, 2023 | baystreet.caBest Times To Visit AntibesJune 16, 2023 | travel.usnews.comClosing Bell: Antibe Therapeutics Inc up on Monday (ATE)June 13, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Friday (ATE)June 3, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc up on Thursday (ATE)May 19, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Thursday (ATE)April 28, 2023 | theglobeandmail.comAntibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials SummitApril 25, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc up on Tuesday (ATE)April 18, 2023 | theglobeandmail.comAntibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 18, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc down on Monday (ATE)April 17, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc flat on Friday (ATE)April 14, 2023 | theglobeandmail.comAntibe Provides April 2023 Corporate UpdateApril 11, 2023 | finance.yahoo.comClosing Bell: Antibe Therapeutics Inc flat on Monday (ATE)April 11, 2023 | theglobeandmail.comClosing Bell: Antibe Therapeutics Inc down on Thursday (ATE)April 7, 2023 | theglobeandmail.comAntibe Reports Q3 2023 Interim Financial and Operating ResultsFebruary 15, 2023 | finance.yahoo.comAntibe Therapeutics: Top 25 Undervalued Toronto Stock Exchange Stocks (ATE)February 5, 2023 | theglobeandmail.comAntibe Reports Q2 2023 Interim Financial and Operating ResultsNovember 15, 2022 | finance.yahoo.comAntibe Closes Previously Announced Strategic Sale of Citagenix SubsidiaryNovember 2, 2022 | finance.yahoo.comAntibe Therapeutics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (ATE)November 1, 2022 | theglobeandmail.comAntibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSE (ATE)September 15, 2022 | theglobeandmail.comAntibe Therapeutics: Stocks trading at Less Than Cash Value on (ATE)September 12, 2022 | theglobeandmail.comATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…September 7, 2022 | finance.yahoo.comAntibe Therapeutics: Bottom 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (ATE)August 18, 2022 | theglobeandmail.comAntibe Therapeutics Inc stock advanced on Friday.August 2, 2022 | theglobeandmail.comAntibe Therapeutics Announces Amendment to Warrant TermsJune 15, 2022 | nz.finance.yahoo.comAntibe Therapeutics Inc. (ATE.TO)June 3, 2022 | finance.yahoo.comAntibe Therapeutics Announces Strategic Sale of Citagenix SubsidiaryMay 2, 2022 | finance.yahoo.comATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…February 16, 2022 | msn.comATE.TO: First Human PK/PD Studies Underway in Otenaproxesul’s Post-Operative Pain Program…February 16, 2022 | finance.yahoo.comAntibe Therapeutics Inc. (TSE:ATE) Given Consensus Rating of "Buy" by AnalystsShares of Antibe Therapeutics Inc. (TSE:ATE) have received an average recommendation of "Buy" from the six research firms that are currently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.January 2, 2022 | marketbeat.com Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW ATE Media Mentions By Week ATE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATE News Sentiment▼0.000.47▲Average Medical News Sentiment ATE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATE Articles This Week▼00▲ATE Articles Average Week Get Antibe Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Microbix Biosystems News Aeterna Zentaris News Sirona Biochem News Resverlogix News Kane Biotech News Hemostemix News Innovotech News Aptose Biosciences News Quest PharmaTech News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (TSE:ATE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antibe Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
